Chemistry:Lu 29-252
From HandWiki
Short description: Sigma σ2 receptor ligand
 | |
| Clinical data | |
|---|---|
| Other names | Lu-29-252; LU-29252; LU29252; Lu 29–252 |
| Drug class | Sigma σ2 receptor ligand |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| PubChem SID | |
| Chemical and physical data | |
| Formula | C28H36N2O2 |
| Molar mass | 432.608 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lu 29-252 is a selective sigma σ2 receptor ligand which was under development for the treatment of anxiety disorders but was never marketed.[1][2][3][4][5] It reached the preclinical stage of development prior to the discontinuation of its development.[1] The drug was under development by Lundbeck.[1]
References
- ↑ 1.0 1.1 1.2 "LU 29252". AdisInsight. Springer Nature Switzerland AG. 23 May 1995. https://adisinsight.springer.com/drugs/800003571.
- ↑ "LU-29252". Therapeutic Target Database (TTD). https://idrblab.net/ttd/data/drug/details/d0t8hu.
- ↑ "Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems". European Journal of Pharmacology 368 (2–3): 183–196. March 1999. doi:10.1016/s0014-2999(99)00025-4. PMID 10193654.
- ↑ "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal (Pleiades Publishing Ltd) 5 (2): 83–91. 2011. doi:10.1134/s1819712411010028. ISSN 1819-7124.
- ↑ "Sigma receptors [σRs: biology in normal and diseased states"]. Journal of Receptor and Signal Transduction Research 36 (4): 327–388. August 2016. doi:10.3109/10799893.2015.1015737. PMID 26056947.
 |  |
